Beyond HTA: Pricing Negotiations and Managed Entry Agreements across Europe
- Comparison of five European markets in one day
- Learn from experts and ask your invidivual questions
- Officially certified to the ISO 9001 and ISO 21001 standards
Online-Seminar
Ab
1.290,00 €
zzgl. MwSt.
Leistungen & Ablauf
Veranstaltung - 1.290,-€ zzgl. MwSt.
The participation fee includes documentation for download, a certificate, access to the Learning Space and technical support including PreMeeting.
Buchungsdetails
Online-Seminar
Ab
1.290,00 €
zzgl. MwSt.
Leistungen & Ablauf
Veranstaltung - 1.290,-€ zzgl. MwSt.
The participation fee includes documentation for download, a certificate, access to the Learning Space and technical support including PreMeeting.
This seminar gives you a clear, comparative understanding of how innovative pricing and reimbursement agreements are structured and negotiated across the UK, Italy, France, Spain, and Germany.
Your speakers
Claire Blaney
Kintiga Ireland, Cambridgeshire, UNITED KINGDOM
Country Manager for Ireland and EU HTA lead
Your speaker
Claire Blaney
Kintiga Ireland, Cambridgeshire, UNITED KINGDOM
Country Manager for Ireland and EU HTA lead
Alain Estival
Cemka, Bourg-La-Reine, FRANCE
Market Access & Pricing Scientific Director
Your speaker
Alain Estival
Cemka, Bourg-La-Reine, FRANCE
Market Access & Pricing Scientific Director
Dr. Lydia Frick
Kintiga (SKC Beratungsgesellschaft mbH), Hannover, GERMANY
Director Market Access
Your speaker
Dr. Lydia Frick
Kintiga (SKC Beratungsgesellschaft mbH), Hannover, GERMANY
Director Market Access
Bernd Schollmeier
Helvetic Consulting GmbH, Zug, SWITZERLAND
Founder & Owner
Your speaker
Bernd Schollmeier
Helvetic Consulting GmbH, Zug, SWITZERLAND
Founder & Owner
Marta Taboada Rodríguez
World Health Management, Madrid, SPAIN
Partner, Head of Market Access Department Pharmaceutical Industry;
25 years of experience in health facilities and Hospital administration. 6 years of experience…
Your speaker
Marta Taboada Rodríguez
World Health Management, Madrid, SPAIN
Partner, Head of Market Access Department Pharmaceutical Industry;
25 years of experience in health facilities and Hospital administration. 6 years of experience in Market Access and Institutional Relations (RIMA).
Teresa Otero
World Health Management, Madrid, Spain
Expert in pharmaceutical law and drug evaluation and senior consultant
Your speaker
Teresa Otero
World Health Management, Madrid, Spain
Expert in pharmaceutical law and drug evaluation and senior consultant
What to Expect
- United Kingdom: Beyound Patient Access Schemes - What is now negotiable?
- Italy: Payment by results and managed entry agreements
- France: CEPS agreements
- Spain: the P&R system, negotiations with the DGCBSSNS, managed entry agreements, and Patient Access Schemes
- Germany: AMNOG and the prospective cohort model; EU HTA and the 2027 price negotiations
Who Should Attend
This seminar addresses professionals from the pharmaceutical and biotech industry working in market access, pricing and reimbursement, health economics and commercial strategy. It is equally relevant for those responsible for launch planning of innovative or high-cost therapies who want a comparative European perspective.
Objective of the Event
This seminar gives you a clear, comparative understanding of how innovative pricing and reimbursement agreements are structured and negotiated across the UK, Italy, France, Spain and Germany. You will learn to distinguish financial-based, performance-based, and mixed models and understand the regulatory logic behind each market.
The direct exchange with experienced experts from across Europe allows you to ask the questions that matter for your own projects.
Your Benefit
After attending, you will be able to...
#assess which agreement types fit a given product and market
- apply insights from concrete cases in high-cost and advanced therapies
Programme
9:00 am - 5:00 pm seminar
You may dial in 30 minutes in advance
09:00
09:15
Claire Blaney
- Threshold Shifts
- NICE Flexibility
- What is now negotiable
- Implications of EUHTA
10:30
Bernd Schollmeier
- Payment by results mechanism
- Success-dependent refunds for non-responders via AIFA registry
- Managed entry agreements (financial-based, performance-based, mixed models)
11:45
12:00
Alain Estival
- Pricing mechanism in France
- Negotiation processes (laws/ other guidances/reports)
- Types of agreements (example of ATMP pricing)
13:15
14:00
Marta Taboada Rodríguez, Teresa Otero
- Spanish P&R system
- Stakeholders in Spain
- Negotiation with DGCBSSNS
- Changes in the evaluation process in Spain: what is already in place and what is expected to come
- How will EU-HTA fit into the current system?
- MEAs in Spain
- Patient Access Schemes
15:30
15:45
Dr. Lydia Frick
- Zolgensma, Spinraza, Kymriah, Yescarta - lessons learnt
- Performance-based agreements on the horizon?
- Outlook: EU HTA, AMNOG and National Price Negotiations 2027
- What can be transferred from other countries?
- What are the implications of the GKV-Beitragssatzstabilisierungsgesetz?
17:00
Welcome
09:15
UK: Beyond Patient Access Schemes (PAS)
UK: Beyond Patient Access Schemes (PAS)
Claire Blaney
- Threshold Shifts
- NICE Flexibility
- What is now negotiable
- Implications of EUHTA
10:30
Italy: Payment by Results - AIFA Registry
Italy: Payment by Results - AIFA Registry
Bernd Schollmeier
- Payment by results mechanism
- Success-dependent refunds for non-responders via AIFA registry
- Managed entry agreements (financial-based, performance-based, mixed models)
Break
12:00
France: CEPS Agreements
France: CEPS Agreements
Alain Estival
- Pricing mechanism in France
- Negotiation processes (laws/ other guidances/reports)
- Types of agreements (example of ATMP pricing)
Lunch break
14:00
Market Access & Pricing in Spain
Market Access & Pricing in Spain
Marta Taboada Rodríguez, Teresa Otero
- Spanish P&R system
- Stakeholders in Spain
- Negotiation with DGCBSSNS
- Changes in the evaluation process in Spain: what is already in place and what is expected to come
- How will EU-HTA fit into the current system?
- MEAs in Spain
- Patient Access Schemes
Break
15:45
Germany: AMNOG and the Prospective Cohort Model
Germany: AMNOG and the Prospective Cohort Model
Dr. Lydia Frick
- Zolgensma, Spinraza, Kymriah, Yescarta - lessons learnt
- Performance-based agreements on the horizon?
- Outlook: EU HTA, AMNOG and National Price Negotiations 2027
- What can be transferred from other countries?
- What are the implications of the GKV-Beitragssatzstabilisierungsgesetz?
End of the seminar
Downloads
Market Access: Basic Concepts and Processes
Market Access: Basic Concepts and Processes
HerunterladenWeitere Informationen
Technical requirements
You need a reliable Internet connection to take part in our online events. To have the best possible learning experience, we recommend that you use the latest version of the Microsoft Edge or Google Chrome browsers. You will need a headset, loudspeaker or telephone to play the audio. Further information is available here. Please check beforehand that your microphone or headset and camera are working properly. Do not access our services from a VPN since there are issues with the audio over such connections.
We have integrated Zoom video conferencing software into our Learning Space for our online training courses. If you are not authorised to use Zoom, please get in touch with us so we can make alternative arrangements for you to take part in our online training.
Free pre-meeting and technology check
You can attend one of our pre-meetings and explore our Learning Space free of charge. Registration is not required. You can find available dates for a pre-meeting in your customer portal. Click the green ‘Participate’ button in the pre-meeting in the customer portal and you will be redirected to the Learning Space.
The pre-meeting gives you the opportunity to explore our Learning Space and to familiarise yourself with the technology to start off your online training on the right foot. This is a non-binding offer for all our customers and not a prerequisite for participation. If a pre-meeting date does not suit you but you would still like a technology check, please contact us.
Our Recommendations
Münchner Gesundheitspolitik-Runde 2026
Politische Gespräche vor Ort in München: Dr. Stephan Pilsinger, MdB im Gespräch mit Ärzteschaft, Apothekerschaft, Krankenkassen & IndustrieSprache: Deutsch
Market Access & Pricing für Arzneimittel mit Companion Diagnostics (CDx)
Targeted Therapies, Biomarker und Companion Diagnostics - Konsequenzen für AMNOG, Erstattung und Produkt-LaunchSprache: Deutsch
Der deutsche Rheumatologie-Markt: Abrechnung und Erstattung kompakt
Preisbildung, Abrechnung und Erstattung - hier erhalten Sie kompaktes Know-how für den Rheumatologie-Markt, sowohl im Hinblick auf Fertigarzneimittel als auch für Infusionen und Zubereitungen.Sprache: Deutsch
GKV-Reformen 2026 mit Arzneimittelrelevanz
GKV-Beitragssatzstabilisierungsgesetz, Krankenhausreform und weitere GKV-Neuerungen - hier erhalten Sie kompakte Informationen der StakeholderSprache: Deutsch
Further Information
List of abbreviations pharma & healthcare
Many abbreviations are used in pharma & healthcare. Download the list of the most important ones.
Newsletter on trends and findings
Stay up to date - we regularly inform you about new regulatory and professional developments.
We guarantee the highest quality
We are now officially certified to ISO 9001 and ISO 21001 standard.
Your Contact Person
We are happy to advise you personally and individually.
Dr. Henriette Wolf-Klein
Bereichsleiterin Pharma & Healthcare
+49 6221 500-680
h.wolf-klein@forum-institut.de